Lane Brothers & Co’s AbbVie ABBV Stock Holding History

Lane Brothers & Co’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$406K	Buy	1,615 +5	+0.3%	+$1.08K	0.27%	55
2026 Q1	$350K	Buy	1,610 +3	+0.2%	+$665	0.26%	52
2025 Q4	$367K	Buy	+1,607	New	+$366K	0.27%	52

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Lane Brothers & Co's ABBV Position: Q2 2026 in Review

Lane Brothers & Co increased its AbbVie (ABBV) stake by 0.31% in Q2 2026, buying an estimated $1.08K and bringing the position to 1,615 shares worth $406K. The position accounts for 0.27% of the portfolio, ranked #55.

Lane Brothers & Co first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Lane Brothers & Co held 1,615 shares of AbbVie worth $406K as of Q2 2026.
Lane Brothers & Co bought 5 AbbVie shares in Q2 2026, an estimated $1.08K.
AbbVie made up 0.27% of Lane Brothers & Co's portfolio in Q2 2026, its #55 holding.
Lane Brothers & Co first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Lane Brothers & Co's 13F filing for Q2 2026, filed 5 Aug 2026.